A new early-stage clinical trial has offered rare hope for Huntington’s disease, a fatal inherited disorder with no cure. Researchers used a gene-silencing therapy delivered directly into the brain, aiming to reduce production of the toxic huntingtin protein.
Patients who received the higher dose showed slower progression over three years, with better motor and cognitive preservation than expected. While the trial was small, it marks one of the most promising steps toward actually modifying not just managing the disease.
More studies are needed to confirm safety, long-term effects, and accessibility, but this breakthrough signals a major shift toward gene-based treatments for neurodegenerative disorders.
MBH/PS